Abstract
The adenosine A2A receptor is a member of the G protein-coupled receptor family and mediates multiple physiological effects of adenosine, both at the central nervous system and at peripheral tissues. Increasing evidence relates the A2A receptor with several pathological conditions such as neurodegenerative disorders, inflammation, pharmacological stress, and wound healing renewing the interest in A2A receptor agonists and antagonists as promising leads for drugs. However some of them initially tested in clinical trials presented several side effects, short half-life, lower solubility, and in some cases a lack of effects, perhaps attributable to receptor desensitization or to low receptor density in the targeted tissue. For these reasons it is evident that additional rational chemical modifications of the existing A2A receptor ligands to improve their affinity/selectivity and bioavailability as well as further studies to get new template for A2AAR ligands are necessary. The purpose of this review is to analyze and summarize the past and the present aspects related to the medicinal chemistry of A2A receptor ligands. Moreover their current and possible therapeutic applications have been also highlighted
Keywords: Adenosine, A2A receptor, A2AAR agonist, A2AAR antagonist
Current Topics in Medicinal Chemistry
Title: A2A Receptor Ligands: Past, Present and Future Trends
Volume: 10 Issue: 9
Author(s): C. Manera and G. Saccomanni
Affiliation:
Keywords: Adenosine, A2A receptor, A2AAR agonist, A2AAR antagonist
Abstract: The adenosine A2A receptor is a member of the G protein-coupled receptor family and mediates multiple physiological effects of adenosine, both at the central nervous system and at peripheral tissues. Increasing evidence relates the A2A receptor with several pathological conditions such as neurodegenerative disorders, inflammation, pharmacological stress, and wound healing renewing the interest in A2A receptor agonists and antagonists as promising leads for drugs. However some of them initially tested in clinical trials presented several side effects, short half-life, lower solubility, and in some cases a lack of effects, perhaps attributable to receptor desensitization or to low receptor density in the targeted tissue. For these reasons it is evident that additional rational chemical modifications of the existing A2A receptor ligands to improve their affinity/selectivity and bioavailability as well as further studies to get new template for A2AAR ligands are necessary. The purpose of this review is to analyze and summarize the past and the present aspects related to the medicinal chemistry of A2A receptor ligands. Moreover their current and possible therapeutic applications have been also highlighted
Export Options
About this article
Cite this article as:
Manera C. and Saccomanni G., A2A Receptor Ligands: Past, Present and Future Trends, Current Topics in Medicinal Chemistry 2010; 10 (9) . https://dx.doi.org/10.2174/156802610791268765
DOI https://dx.doi.org/10.2174/156802610791268765 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Nicotinic Receptors for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Microfluidic Methods for Non-Viral Gene Delivery
Current Gene Therapy Patent Selections
Recent Patents on DNA & Gene Sequences The Underestimated Role of Mechanical Stimuli in Brain Diseases and the Relate d In Vitro Models
Current Pharmaceutical Design MicroRNAs and Stem Cells to the Rescue
Current Neurovascular Research Stem Cells: An Overview of the Current Status of Therapies for Central and Peripheral Nervous System Diseases
Current Medicinal Chemistry Allosteric Modulators for Adenosine Receptors: An Alternative to the Orthosteric Ligands
Current Topics in Medicinal Chemistry Calpains as a Target for Therapy of Neurodegenerative Diseases: Putative Role of Lithium
Current Drug Metabolism Cardiovascular Risk and Endothelial Dysfunction: The Preferential Route for Atherosclerosis
Current Pharmaceutical Biotechnology After Thalidomide – Do We Have the Right Balance Between Public Health and Intellectual Property
Reviews on Recent Clinical Trials Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology CHF5074 Protects SH-SY5Y Human Neuronal-like Cells from Amyloidbeta 25-35 and Tumor Necrosis Factor Related Apoptosis Inducing Ligand Toxicity In Vitro
Current Alzheimer Research Editorial (Thematic Issue: Neuroprotective Effects of Li - It is Elementary)
Current Alzheimer Research C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current Neuropharmacology The Effect of Acori Graminei Rhizoma and Extract Fractions on Spatial Memory and Hippocampal Neurogenesis in Amyloid Beta 1-42 Injected Mice
CNS & Neurological Disorders - Drug Targets The Interplay between G-quadruplex and Transcription
Current Medicinal Chemistry Editorial [Medicinal Chemistry of Novel Therapeutics (Guest Editor: Tanaji Talele)]
Current Bioactive Compounds Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry Biomarkers for Alzheimer's Disease Diagnosis
Current Alzheimer Research